SEC Form 4 · accession 0000899243-17-003618

CRISPR Therapeutics AG · CRSP

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Oct 24, 2016

Accepted (ET)

Feb 10, 2017 · 7:23 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001674416

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Shares^F1,F2	Oct 24, 2016	C	2,354,050	$0.00	A	2,354,050	I	See Footnote
Common Shares^F1,F2	Oct 24, 2016	C	191,764	$0.00	A	2,545,814	I	See Footnote
Common Shares^F2	Oct 24, 2016	P	56,000	$14.00	A	2,601,814	I	See Footnote

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Series A-3 Preferred Shares^F1,F2	$0.00	Oct 24, 2016	C	2,354,050	D	—	—	Common Shares	2,354,050	0	I
Series B Preferred Shares^F1,F2	$0.00	Oct 24, 2016	C	191,764	D	—	—	Common Shares	191,764	0	I

F1These securities were convertible at any time on a one-for-one basis into shares of the Issuer's Common Stock at the holder's election and automatically upon the closing of the Issuer's initial public offering. These securities do not have an expiration date.
F2These shares are held by Abingworth Bioventures VI, LP ("Abingworth"). Abingworth Bioventures VI GP LP ("Abingworth GP") serves as the general partner of Abingworth. Abingworth General Partner VI LLP, serves as the general partner of Abingworth GP. Abingworth (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VI LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by Abingworth. The Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth. The reporting person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.